Results 71 to 80 of about 11,103 (274)
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou+4 more
wiley +1 more source
Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods.
S. K. Zyryanov+2 more
doaj +1 more source
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard+4 more
core +4 more sources
Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab
Mepolizumab and omalizumab induce a distinct clinical effect. Mepolizumab and omalizumab induce both common and treatment‐specific metabolic and protein profiles over time in patients with severe asthma. Multiomic integration and receiver operating characteristic curve analyses reveal a specific set of biomolecules suggesting their value as potential ...
Nuria Contreras+16 more
wiley +1 more source
New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core +1 more source
A retrospective cohort of newly diagnosed treatment‐naive patients with ABPA in Japan who were followed up for up to 3 years after the primary diagnosis was analyzed to explore the clinical remission rate and clinical characteristics of ABPA resistant to standard treatment or prone to exacerbation during/after treatment.
Jun Tanaka+19 more
wiley +1 more source
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy+4 more
core +3 more sources
Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities
ABSTRACT Over the past 70 years, oral corticosteroids (OCS) have played an important role in the management of acute and chronic asthma; however, their use is associated with an increased incidence of adverse events, chronic diseases such as osteoporosis and diabetes, and mortality, as well as increased healthcare resource utilization and costs ...
G. Walter Canonica+9 more
wiley +1 more source
Anaphylaxis to three humanized antibodies for severe asthma: a case study
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo+9 more
doaj +1 more source
MEPOLYP was a pooled analysis of 1037 patients with SAEP[±]CRSwNP. Mepolizumab was associated with a reduction in CSEs, OCS use, and BEC, and improved lung function and ACT score. Over 47% of patients fulfilled ≥ 3 clinical remission criteria. When compared, there was a 30.0% incremental benefit of mepolizumab in reducing CSEs for patients with SAEP ...
Florence Schleich+14 more
wiley +1 more source